190 related articles for article (PubMed ID: 3390809)
1. Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice.
Saito M; Nanjo M; Kataoka M; Moriya Y; Sugawara Y; Yoshida T; Ishida N
Cancer Res; 1988 Aug; 48(15):4163-7. PubMed ID: 3390809
[TBL] [Abstract][Full Text] [Related]
2. Adoptive immunotherapy in tumor-bearing mice with OK-432-induced killer cells.
Ujiie T
Jpn J Exp Med; 1988 Apr; 58(2):109-14. PubMed ID: 3261814
[TBL] [Abstract][Full Text] [Related]
3. [Induction of LAK cells in peritoneal cavity of mice after ip injection of OK-432 and antitumor effect of these LAK cells].
Ishida N; Saito M; Nanjo M
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2681-90. PubMed ID: 6508321
[TBL] [Abstract][Full Text] [Related]
4. [Successful adoptive immunotherapy with OK432-inducible activated natural killer cells on tumor-bearing mice].
Yamaue H; Tanimura H; Iwahashi M; Tani M; Tsunoda T; Tabuse K
Nihon Gan Chiryo Gakkai Shi; 1989 Dec; 24(11):2546-55. PubMed ID: 2614190
[TBL] [Abstract][Full Text] [Related]
5. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
Mizushima Y; Morikage T; Hirata H; Sato M; Sakamoto K; Yano S
J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
[TBL] [Abstract][Full Text] [Related]
6. Local adoptive immunotherapy of human head and neck cancer xenografts in nude mice with lymphokine-activated killer cells and interleukin 2.
Sacchi M; Snyderman CH; Heo DS; Johnson JT; d'Amico F; Herberman RB; Whiteside TL
Cancer Res; 1990 May; 50(10):3113-8. PubMed ID: 2334906
[TBL] [Abstract][Full Text] [Related]
7. Augmentation by OK-432 of generation of culture-induced killer cells.
Ujiie T
Jpn J Exp Med; 1987 Jun; 57(3):153-61. PubMed ID: 3682231
[TBL] [Abstract][Full Text] [Related]
8. In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2.
Spiess PJ; Yang JC; Rosenberg SA
J Natl Cancer Inst; 1987 Nov; 79(5):1067-75. PubMed ID: 3500355
[TBL] [Abstract][Full Text] [Related]
9. Analysis of antitumor effects of OK-432 against syngeneic mouse fibrosarcoma: combination effect of OK-432 and recombinant lymphokines.
Nanjo M; Moriya Y; Hashimoto S; Kataoka M; Saito M; Yoshida T; Ishida N
Int J Immunopharmacol; 1991; 13(2-3):205-15. PubMed ID: 1906439
[TBL] [Abstract][Full Text] [Related]
10. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
11. [Effect of combined immunotherapy using two different BRMs; OK-432 and IL-2-cultured lymphocytes].
Kan N; Hori T; Ohgaki K; Inamoto T; Kodama H; Tobe T
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1298-306. PubMed ID: 3488027
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy-mediated immune response against subcutaneous mouse tumors.
Korbelik M; Dougherty GJ
Cancer Res; 1999 Apr; 59(8):1941-6. PubMed ID: 10213504
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
Takai N; Tanaka R; Yoshida S; Hara N; Saito T
Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
[TBL] [Abstract][Full Text] [Related]
14. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation.
Saito M; Ichimura O; Kataoka M; Moriya Y; Ueno K; Sugawara Y; Nanjo M; Ishida N
Cancer Immunol Immunother; 1986; 22(3):161-8. PubMed ID: 2425968
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells.
Okamoto M; Ohe G; Furuichi S; Nishikawa H; Oshikawa T; Tano T; Ahmed SU; Yoshida H; Moriya Y; Matsubara S; Ryoma Y; Saito M; Sato M
Anticancer Res; 2002; 22(6A):3229-39. PubMed ID: 12530069
[TBL] [Abstract][Full Text] [Related]
16. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of adoptive immunotherapy: improved methods for in vivo tracking of tumor-infiltrating lymphocytes and lymphokine-activated killer cells.
Wallace PK; Palmer LD; Perry-Lalley D; Bolton ES; Alexander RB; Horan PK; Yang JC; Muirhead KA
Cancer Res; 1993 May; 53(10 Suppl):2358-67. PubMed ID: 8485722
[TBL] [Abstract][Full Text] [Related]
18. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
19. [Role of the spleen in OK-432 immunotherapy and characterization of effector cells].
Yamagishi H; Naito K; Maeda Y; Kobayashi M; Kurioka H; Fujimori C; Tanaka T; Hashimoto I
Gan To Kagaku Ryoho; 1983 Jul; 10(7):1670-8. PubMed ID: 6870309
[TBL] [Abstract][Full Text] [Related]
20. New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils.
Hayashi Y; Torisu M
Surgery; 1990 Jan; 107(1):74-84. PubMed ID: 2404351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]